Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables (2016 - 2025)

Historic Receivables for RedHill Biopharma (RDHL) over the last 10 years, with Q2 2025 value amounting to $5.4 million.

  • RedHill Biopharma's Receivables rose 44928.13% to $5.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.4 million, marking a year-over-year increase of 44928.13%. This contributed to the annual value of $2.5 million for FY2024, which is 200.69% down from last year.
  • RedHill Biopharma's Receivables amounted to $5.4 million in Q2 2025, which was up 44928.13% from $2.5 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Receivables ranged from a high of $36.0 million in Q3 2022 and a low of $974000.0 during Q2 2024
  • Its 5-year average for Receivables is $19.0 million, with a median of $24.6 million in 2021.
  • In the last 5 years, RedHill Biopharma's Receivables skyrocketed by 125736.75% in 2021 and then crashed by 9249.44% in 2023.
  • Over the past 5 years, RedHill Biopharma's Receivables (Quarter) stood at $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then plummeted by 92.49% to $2.6 million in 2023, then dropped by 2.01% to $2.5 million in 2024, then soared by 110.71% to $5.4 million in 2025.
  • Its Receivables stands at $5.4 million for Q2 2025, versus $2.5 million for Q4 2024 and $974000.0 for Q2 2024.